NEWS
Daré Bioscience Reports Second Quarter 2024 Financial Results and Provides Company Update
Daré Bioscience (NASDAQ: DARE) reported Q2 2024 financial results and provided a company update. Key highlights include:
1. Ongoing enrollment in the OvaprenePhase 3 contraceptive efficacy study across the U.S.
2. Progress on Sildenafil Cream, 3.6% for female sexual arousal disorder, awaiting FDA feedback on Phase 3 study design.
3. Cash and cash equivalents of $16.4 million as of June 30, 2024.
4. Q2 2024 R&D expenses decreased 19% to $4.9 million, while G&A expenses decreased to $2.4 million.
5. Received $22 million in April 2024 from a non-dilutive royalty monetization transaction.
The company continues to focus on advancing its late-stage candidates, all representing first-in-category opportunities in women's health.
1. Ongoing enrollment in the OvaprenePhase 3 contraceptive efficacy study across the U.S.
2. Progress on Sildenafil Cream, 3.6% for female sexual arousal disorder, awaiting FDA feedback on Phase 3 study design.
3. Cash and cash equivalents of $16.4 million as of June 30, 2024.
4. Q2 2024 R&D expenses decreased 19% to $4.9 million, while G&A expenses decreased to $2.4 million.
5. Received $22 million in April 2024 from a non-dilutive royalty monetization transaction.
The company continues to focus on advancing its late-stage candidates, all representing first-in-category opportunities in women's health.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
Spread kindness and love. Life is short. Don’t let greed eat you.
1196Followers
74Following
8481Visitors
Follow